Latest Licensing Agreements News

ION Video has reported a $4.52 million FY2026 loss and a $3.21 million operating cash drain, even as a post-year-end $4.25 million placement lifted its balance sheet. Auditors have preserved their opinion but flagged material uncertainty over the company’s ability to continue as a going concern.

Radiopharm Theranostics reported a A$56.3 million comprehensive loss for fiscal 2026, with operating cash outflows rising to A$52.8 million and cash falling to A$4.1 million. The company says further funding is required, while auditors flag a material uncertainty over its ability to continue as a going concern.

Vulcan Energy has started commercial-scale production in Germany of VULSORB, the proprietary adsorbent at the centre of its planned direct lithium extraction process. The material will supply first-fill volumes for Project Lionheart, although lithium production remains targeted for the second half of 2028.

Vectus Biosystems swung to a $1.56 million FY2026 profit, but the result was driven largely by the sale of its VB4-P5 compound for XORTX shares and warrants rather than recurring operations. The company is now directing its resources towards VB0004 while its auditor flags material uncertainty over ongoing funding.

Ionic Rare Earths is pushing toward commercial magnet recycling in Belfast and the United States, but its FY2026 report flags a material uncertainty over its ability to continue as a going concern. The company reported a larger A$14.9 million loss and A$13.9 million in operating cash outflows, despite government support and new strategic partnerships.

ION Video has secured an oversubscribed $4.25 million placement to fund independent trials of its video technology, with directors and management committing a further $1.2 million subject to shareholder approval. The capital will be used to test whether ION’s architecture can deliver measurable technical and financial benefits in real operating environments.

TALi Digital (ASX:TD1) is raising up to $3.3 million through a Security Purchase Plan and Placement to fund its acquisition of Datasphere Analytics and advance its AI-driven education platform.

Audeara Limited delivered record FY26 revenue of $4.45 million, driven by a 45% surge in Australian wholesale sales and progress in AI audio licensing with OPTEK Microelectronics. The company narrowed its loss and advanced Auracast deployments across retirement villages and education sectors.

Weebit Nano surged to record revenue of $15.3 million in FY26, fueled by key licensing deals and product tape-outs, while investing heavily in R&D and AI initiatives. Despite a $54.9 million loss, a $102 million capital raise leaves the company well-positioned for growth.

Argent BioPharma has secured a key FDA regulatory milestone with the establishment of an Investigational New Animal Drug (INAD) file for its CannEpil veterinary program, targeting cancer-related pain in companion animals.

Ainsworth Game Technology’s first half 2026 results reveal a sharp revenue drop driven by North American and Latin American market pressures, offset partially by Asia Pacific growth and a key patent licensing deal.

Acrux Limited reported a 46% revenue increase to $6.6 million in FY26, driven by US generic product royalties and licensing milestones, while narrowing its net loss by 90%. The company is pivoting towards developing a female testosterone therapy with encouraging Phase II data and active regulatory engagement.